Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 5/20 | 0.42 |
| ▸ | CTSK | P43235 | 6/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.36 |
| ▸ | PDE1A | P54750 | 1/20 | 0.35 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.35 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 5/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3579227 | 0.95 | ALOX5 (0.41) | ALOX5CTSKPIK3CDPDE1APDE1B | |
| SCHEMBL3568405 | 0.93 | ALOX5 (0.43) | ALOX5CTSKPIK3CDPDE1APDE1B | |
| SCHEMBL3574601 | 0.92 | ALOX5 (0.42) | ALOX5CTSKPIK3CDPDE1APDE1B | |
| SCHEMBL3570551 | 0.92 | ALOX5 (0.44) | ALOX5CTSKPIK3CDPDE1APDE1B | |
| SCHEMBL3576764 | 0.92 | ALOX5 (0.41) | ALOX5CTSKPIK3CDPDE1APDE1B | |
| SCHEMBL3575020 | 0.90 | ALOX5 (0.43) | ALOX5CTSKPIK3CDPDE1APDE1B | |
| SCHEMBL3579556 | 0.89 | ALOX5 (0.42) | ALOX5CTSKPIK3CDPDE1APDE1B | |
| SCHEMBL3568598 | 0.89 | ALOX5 (0.42) | ALOX5PIK3CDPDE1APDE1BPDE1C | |
| SCHEMBL3570959 | 0.88 | ALOX5 (0.47) | ALOX5CTSKPIK3CDPDE1APDE1B | |
| SCHEMBL3574960 | 0.88 | ALOX5 (0.41) | ALOX5PIK3CDPDE1APDE1BPDE1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7674811-B2 | 5-lipoxygenase inhibitors | RANBAXY LABORATORIES LIMITED (IN) | 2010-03-09 | — | — | US | claimed |
| US-20080021080-A1 | 5-LIPOXYGENASE INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2008-01-24 | — | — | US | claimed |
| EP-1834953-A1 | Tetrahydropyrane derivatives as 5-lipoxygenase inhibitors | Ranbaxy Laboratories Limited (IN) | 2007-09-19 | — | — | EP | claimed |
| US-7674811-B2 | 5-lipoxygenase inhibitors | RANBAXY LABORATORIES LIMITED (IN) | 2010-03-09 | — | — | US | disclosed |
| US-20080021080-A1 | 5-LIPOXYGENASE INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2008-01-24 | — | — | US | disclosed |
| EP-1834953-A1 | Tetrahydropyrane derivatives as 5-lipoxygenase inhibitors | Ranbaxy Laboratories Limited (IN) | 2007-09-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021080-A1 | 5-LIPOXYGENASE INHIBITORS | ALOX5, ALOX15B, ALOX15 | ALOX5 1/4885CTSK 1763/4885PIK3CD 2405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.